Skip to main content

Advertisement

Fig. 2 | BMC Research Notes

Fig. 2

From: Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors

Fig. 2

Effect of the plasmin inhibitor DX-1000, the plasma kallikrein inhibitor lanadelumab of the anti-lanadelumab antibody M293-D02 on iBK generation induced by Kontact-APTT or tPA (concentrations, incubation periods as indicated). The inhibitors were added 5 min before the addition of stimuli to plasma samples at time zero. Enalaprilat (130 nM) was present in all tubes. Values are mean ± S.E.M. (number of subjects indicated by n). The Kruskal–Wallis ANOVA applied to values of iBK from blood under each of the 2 stimuli indicated significant differences (P = 0.003 for Kontact-APTT, P = 0.0005 for tPA). Selected pairs of values were compared using Dunn’s multiple comparison test. Each value vs. common control: *P < 0.05; **P < 0.01. Effect of lanadelumab alone vs. its combination with M293-D02: P < 0.05

Back to article page